In recent years, the use of weight-loss medications such as Ozempic, Wegovy, and Mounjaro has gained attention, particularly within the fashion industry. Initially, Ozempic was mainly prescribed for type 2 diabetes, but it began to be used off-label for weight loss among certain groups. Today, various celebrities have openly discussed their use of these medications, which are also now prescribed on the NHS.
However, access to these weight-loss drugs is not uniform. More than 1.5 million people in the UK reportedly use these medications, yet a significant portion pays privately, with costs typically ranging from £100 to £350 monthly. The NHS has set strict eligibility criteria, often limiting prescriptions to patients with a BMI over 35, which leads to concerns about variations in access or a “postcode lottery.” Patients in regions with higher thresholds may find it more challenging to obtain prescriptions, according to Martin Fidock, managing director of Ovivia.
As demand for these drugs increases, pharmaceutical companies have seen and responded to this trend, although reports of price increases for medications like Mounjaro have raised worries about affordability. NHS England has acknowledged regional disparities in access and is considering measures to expand availability, but concerns persist regarding access and affordability for disadvantaged communities.
The introduction of these medications has raised ethical questions regarding health inequities and the potential for further marginalization of lower-income individuals. Critics argue that focusing on medication may detract from addressing underlying issues within the food system and obesity prevention initiatives requiring investment. As the landscape of obesity management evolves, the effectiveness and equity of access to these treatments remain focal points for health officials and patients alike.
Source: https://www.bbc.com/news/articles/cre5xp83394o?at_medium=RSS&at_campaign=rss